| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Diabetes, Advancing Chronic Kidney Disease Management Panel
Test Code91713
CPT Codes
80051, 82570, 82043, 82565, 85018, 83970, 82310, 84100, 82306
Includes
Electrolyte Panel (Carbon Dioxide, Chloride, Potassium, Sodium)
Albumin, Random Urine with Creatinine
Creatinine, Serum
Hemoglobin
PTH, Intact and Calcium
Phosphate (as Phosphorus)
Vitamin D, 25-Hydroxy, Total, Immunoassay
Albumin, Random Urine with Creatinine
Creatinine, Serum
Hemoglobin
PTH, Intact and Calcium
Phosphate (as Phosphorus)
Vitamin D, 25-Hydroxy, Total, Immunoassay
Preferred Specimen
3 mL serum and
Whole blood collected in one full EDTA (lavender-top) tube and
1.5 mL plasma collected for PTH, Intact in an EDTA (lavender-top) tube and
10 mL random urine - no preservative submitted in a sterile plastic leak-proof container
Whole blood collected in one full EDTA (lavender-top) tube and
1.5 mL plasma collected for PTH, Intact in an EDTA (lavender-top) tube and
10 mL random urine - no preservative submitted in a sterile plastic leak-proof container
Patient Preparation
Patient should fast 9-12 hours prior to collection
Minimum Volume
1 mL serum • 1 mL whole blood collected in an EDTA (lavender-top) tube or 0.5 mL whole blood collected in a Microtainer EDTA tube • 1 mL plasma • 2 mL random urine
Other Acceptable Specimens
2 mL (1 mL minimum) frozen serum for PTH, Intact • Whole blood from a full EDTA (tan-top) tube
Instructions
Whole blood: Maintain specimen at room temperature. Do not refrigerate. If multiple draw, collect EDTA (lavender-top) tube last. Traumatic draw can introduce thromboplastin and trap WBC and platelets. Refrigeration can precipitate fibrin and trap WBC and platelets.
Plasma: Centrifuge and transfer EDTA plasma to a transport tube. Label as PLASMA for the PTH, Intact.
Note: If drawn with lead testing, EDTA (tan-top) is required.
Plasma: Centrifuge and transfer EDTA plasma to a transport tube. Label as PLASMA for the PTH, Intact.
Note: If drawn with lead testing, EDTA (tan-top) is required.
Transport Temperature
See individual tests
Specimen Stability
Serum for Electrolytes, Phosphorus and Creatinine
Room temperature: 48 hours
Refrigerated: 72 hours
Frozen: 28 days
Serum for 25OH-Vit D
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 28 days
Serum for Calcium
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 28 days
Whole blood
Room temperature: 48 hours
Refrigerated: 48 hours (may cause platelet clumping)
Frozen: Unstable
EDTA plasma for PTH, Intact
Room temperature: 48 hours
Refrigerated: 72 hours
Frozen: 24 hours
Serum for PTH, Intact
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Random urine
Room temperature: 7 days
Refrigerated: 7 days
Frozen 28 days
Room temperature: 48 hours
Refrigerated: 72 hours
Frozen: 28 days
Serum for 25OH-Vit D
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 28 days
Serum for Calcium
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 28 days
Whole blood
Room temperature: 48 hours
Refrigerated: 48 hours (may cause platelet clumping)
Frozen: Unstable
EDTA plasma for PTH, Intact
Room temperature: 48 hours
Refrigerated: 72 hours
Frozen: 24 hours
Serum for PTH, Intact
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Random urine
Room temperature: 7 days
Refrigerated: 7 days
Frozen 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
See individual tests
Methodology
See individual tests
Setup Schedule
See individual assays
Clinical Significance
This panel is designed for individuals diagnosed as having diabetes mellitus whose kidney disease has advanced to Stage 3/4 impairment. The panel affords the opportunity to assess electrolytes, phosphorus, serum creatinine/eGFR, hemoglobin, microalbumin, parathyroid hormone, calcium, and vitamin D.
The grouping of these tests, readily identifiable as elements that adhere to guideline recommendations, is intended to facilitate the ready adherence to professional society clinical practice guidelines. Components of the testing related to the Management of CKD in diabetes, as outlined in the Standards of Medical Care in Diabetes 2013. These recommendations are in broad agreement with those published by the National Kidney Foundation and the American Association of Clinical Endocrinologists.
The grouping of these tests, readily identifiable as elements that adhere to guideline recommendations, is intended to facilitate the ready adherence to professional society clinical practice guidelines. Components of the testing related to the Management of CKD in diabetes, as outlined in the Standards of Medical Care in Diabetes 2013. These recommendations are in broad agreement with those published by the National Kidney Foundation and the American Association of Clinical Endocrinologists.
